SLAM
STOK icon

Swiss Life Asset Management’s Stoke Therapeutics STOK Stock Holding History

Swiss Life Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,544
Closed -$213K – 1726
2026
Q1 		$213K Sell
6,544
-254
-4% -$8.33K ﹤0.01% 1345
2025
Q4 		$216K Buy
+6,798
New +$204K ﹤0.01% 1231

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Swiss Life Asset Management's STOK Position: Q2 2026 in Review

Swiss Life Asset Management sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 6,544 shares — an estimated $213K sold.

Swiss Life Asset Management first reported a position in STOK in Q4 2025 and held it in 2 quarters. The position peaked at $216K in Q4 2025. 94 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Swiss Life Asset Management reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Swiss Life Asset Management sold 6,544 Stoke Therapeutics shares in Q2 2026, an estimated $213K.
  • Swiss Life Asset Management first reported a position in Stoke Therapeutics in Q4 2025 and held it in 2 quarters.
  • Swiss Life Asset Management's Stoke Therapeutics position peaked at $216K in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.